These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 6255896)

  • 41. The influence of different adjuvants on the immune response to a synthetic peptide comprising amino acid residues 9-21 of herpes simplex virus type 1 glycoprotein D.
    Geerligs HJ; Weijer WJ; Welling GW; Welling-Wester S
    J Immunol Methods; 1989 Nov; 124(1):95-102. PubMed ID: 2553820
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunogenicity of herpes simplex virus type 1 glycoproteins expressed in vaccinia virus recombinants.
    Blacklaws BA; Krishna S; Minson AC; Nash AA
    Virology; 1990 Aug; 177(2):727-36. PubMed ID: 2164732
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Design of inactivated polyvalent antiherpes vaccines].
    Andonov P; Dundarov S; Bakalov B
    Vopr Virusol; 1979; (6):665-71. PubMed ID: 230648
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of a nucleic acid free herpetic subunit vaccine.
    Cappel R; de Cuyper F; Rickaert F
    Arch Virol; 1980; 65(1):15-23. PubMed ID: 6252864
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Protection against establishment of latent infections in mice immunized with a non-pathogenic herpes simplex virus mutant and reinfected with the pathogenic parental strain.
    Klein RJ; Kaley LA; Friedman-Kien AE
    Vaccine; 1984 Sep; 2(3):219-23. PubMed ID: 6099650
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Contributions of antibody and T cell subsets to protection elicited by immunization with a replication-defective mutant of herpes simplex virus type 1.
    Morrison LA; Knipe DM
    Virology; 1997 Dec; 239(2):315-26. PubMed ID: 9434723
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Humoral and cellular immune responses to an envelope-associated antigen of herpes simplex virus.
    Zaia JA; Palmer EL; Feorino PM
    J Infect Dis; 1975 Dec; 132(6):660-6. PubMed ID: 172562
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genetic immunization against herpes simplex virus. Protection is mediated by CD4+ T lymphocytes.
    Manickan E; Rouse RJ; Yu Z; Wire WS; Rouse BT
    J Immunol; 1995 Jul; 155(1):259-65. PubMed ID: 7602102
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of herpes simplex virus type 1 immunization in protecting against acute and latent infection by herpes simplex virus type 2 in mice.
    McKendall RR
    Infect Immun; 1977 May; 16(2):717-9. PubMed ID: 193798
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Herpes simplex virus type 1 infection in mice with severe combined immunodeficiency (SCID).
    Minagawa H; Sakuma S; Mohri S; Mori R; Watanabe T
    Arch Virol; 1988; 103(1-2):73-82. PubMed ID: 2850780
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of coexpression of IL-2 and herpes simplex virus proteins in recombinant vaccinia virus vectors on levels of induced immunity.
    Allen EM; Weir JP; Martin S; Mercadal C; Rouse BT
    Viral Immunol; 1990; 3(3):207-15. PubMed ID: 2175194
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunized mice challenged with herpes simplex virus by the intranasal route show protection against latent infection.
    Rooney JF; Wohlenberg C; Cremer KJ; Notkins AL
    J Infect Dis; 1989 May; 159(5):974-6. PubMed ID: 2540251
    [No Abstract]   [Full Text] [Related]  

  • 53. Preinfection prophylaxis with herpes simplex virus glycoprotein immunogens: factors influencing efficacy.
    Stanberry LR; Myers MG; Stephanopoulos DE; Burke RL
    J Gen Virol; 1989 Dec; 70 ( Pt 12)():3177-85. PubMed ID: 2558156
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Protection of guinea pigs from primary and recurrent herpes simplex virus (HSV) type 2 cutaneous disease with vaccinia virus recombinants expressing HSV glycoprotein D.
    Wachsman M; Aurelian L; Smith CC; Lipinskas BR; Perkus ME; Paoletti E
    J Infect Dis; 1987 Jun; 155(6):1188-97. PubMed ID: 3033094
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Induction of potent protection against acute and latent herpes simplex virus infection in mice vaccinated with dendritic cells.
    Ghasemi M; Erturk M; Buruk K; Sonmez M
    Cytotherapy; 2013 Mar; 15(3):352-61. PubMed ID: 23579060
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A detergent-soluble extract of virus-infected cells free from infectious virus protects mice from lethal herpes simplex virus infection.
    Ohashi Y; Sakaue Y; Kato S; Wada T; Sato K
    Biken J; 1980 Dec; 23(4):199-204. PubMed ID: 6266395
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The proportion of herpes simplex virus-specific cytotoxic T lymphocytes (Tc) that recognize glycoprotein C varies between individual mice and is dependent on the form of immunization.
    Martin S; Mercadal CM; Weir JP; Rouse BT
    Viral Immunol; 1993; 6(1):21-33. PubMed ID: 8386515
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adjuvant effects of imiquimod on a herpes simplex virus type 2 glycoprotein vaccine in guinea pigs.
    Bernstein DI; Miller RL; Harrison CJ
    J Infect Dis; 1993 Mar; 167(3):731-5. PubMed ID: 8382722
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Augmentation of immunity to herpes simplex virus by in vivo administration of interleukin 2.
    Rouse BT; Miller LS; Turtinen L; Moore RN
    J Immunol; 1985 Feb; 134(2):926-30. PubMed ID: 2981270
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preparation and efficacy of antiherpes type 1 and 2 subunit vaccines.
    Kavaklova L; Dundarov S; Andonov P; Bakalov B; Dundarova D; Brodvarova I
    Acta Virol; 1986 Sep; 30(5):402-10. PubMed ID: 2878588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.